Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage‐Driven Resistance
Microbial Biotechnology · 2026-06 · 19 (6)
DOI: 10.1111/1751-7915.70389 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Biotechnology, online erschienen am 28.05.2026. Verfasst von Salwa E Gomaa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan, China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Pseudomonas Phages, Genetic Fitness. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, the Key R&D and Promotion Projects of Henan Province.
Abstract (Originalsprache)
Phage therapy is increasingly recognised as a potential approach against antibiotic‐resistant infections. Analogous to the rise of antibiotic resistance, bacteria can also evolve phage resistance, a process that frequently entails fitness costs. In this study, a new lytic Pseudomonas aeruginosa phage (Henu5) was isolated and characterised. Henu5 was classified within the Caudoviricetes class and displayed good biological characteristics. The Henu5 genome possesses 92,558 bp of linear dsDNA and a GC content of 49.36%. Additionally, three phage‐resistant mutants, R3, R6 and R14, were isolated and investigated for adaptive trade‐offs. Compared to wild‐type, the phage‐resistant mutants mostly exhibited fitness costs in growth, altered morphology, impaired adsorption, reduced biofilm and pyocyanin production and impaired motility, which was confirmed by transmission electron microscopy, as well as increased susceptibility to various antibiotics. In vivo experiments revealed improved survival, alongside diminished colonisation and pathogenicity. Comparative genomics identified mutations in the genes pilQ (R3 and R14) and pilR (R6), both crucial for type IV pili (T4P) biosynthesis and potentially conferring phage resistance, with additional mutations related to the obtained trade‐offs. Transcriptomic and real‐time quantitative PCR proved that T4P‐related genes, together with the hmgA , galU , wzy , fliG , pslA , mexH and exoY genes, were downregulated in all resistant mutants, while the qscR and mvaT genes were upregulated. Collectively, while phage resistance evolution remains an issue, this study suggests that the fitness costs of the phage‐resistant mutants might be invaluable for effective phage therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan, China.
- Henan International Joint Laboratory for Nuclear Protein Regulation, School of Basic, Medical Sciences, Henan University, Kaifeng, Henan, China.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Förderung
- Henan Provincial Science and Technology Research Project
- the Key R&D and Promotion Projects of Henan Province
Zitieren
APA
Gomaa, S. E., Shen, J., Li, J., Liu, Y., Ma, C., Li, Q., Qi, G., & Teng, T. (2026). Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage‐Driven Resistance. Microbial Biotechnology, 19(6). https://doi.org/10.1111/1751-7915.70389
Vancouver
Gomaa SE, Shen J, Li J, Liu Y, Ma C, Li Q, et al. Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage‐Driven Resistance. Microbial Biotechnology. 2026;19(6). doi:10.1111/1751-7915.70389
BibTeX
@article{Gomaa2026,
author = {Gomaa, Salwa E and Shen, Jiawen and Li, Jingjing and Liu, Yangyang and Ma, Chaonan and Li, Qiming and Qi, Guanbin and Teng, Tieshan},
title = {Isolation of a Novel Lytic Pseudomonas aeruginosa Phage Henu5 and Fitness Costs of Phage‐Driven Resistance},
journal = {Microbial Biotechnology},
year = {2026},
volume = {19},
number = {6},
doi = {10.1111/1751-7915.70389}
}
EUVIMED